Evaluation of Intratumoral Administration of Tumor Necrosis Factor-alpha in Patients with Malignant Glioma

Background: This study assessed safety and efficacy for intratumoral administration of tumor necrosis factor-α (TNF-SAM2) into the post-operative tumor cavity through an Ommaya reservoir for patients with malignant glioma. Materials and Methods: Seven patients with malignant glioma, comprising 3 ca...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2006-11, Vol.26 (6A), p.4027-4032
Main Authors: OSHIRO, Shinya, TSUGU, Hitoshi, KOMATSU, Fuminari, OHNISHI, Hirokazu, UENO, Yushi, SAKAMOTO, Seizaburo, FUKUSHIMA, Takeo, SOMA, Gen-Ichiro
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Female
Glioma - immunology
Glioma - therapy
Humans
Injections, Intralesional
Male
Medical sciences
Middle Aged
Neurology
Treatment Outcome
Tumor Necrosis Factor-alpha - administration & dosage
Tumor Necrosis Factor-alpha - adverse effects
Tumors
Tumors of the nervous system. Phacomatoses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: This study assessed safety and efficacy for intratumoral administration of tumor necrosis factor-α (TNF-SAM2) into the post-operative tumor cavity through an Ommaya reservoir for patients with malignant glioma. Materials and Methods: Seven patients with malignant glioma, comprising 3 cases with glioblastoma multiforme (GBM), 3 cases with anaplastic astrocytoma (AA) and 1 case with malignant ependymoma (ME) were included in the study. All patients were pathologically diagnosed and initially treated with adjuvant therapy (radiation and/or ranimustine and/or systemic TNF-SAM2 infusion) following surgical resection. TNF-SAM2 was administrated into the post-operative tumor cavity through a reservoir at a concentration of 1×10 4 U/body when recurrence was detected, or as initial induction therapy concomitant with radiotherapy. Results: Partial response to this regional immunotherapy was seen in 4 out of 7 patients, and 1 patient with GBM has remained clinically stable for >184 weeks without tumor progression. With AA, 2 cases appeared to display slowed advance and longer times to tumor recurrence or regrowth. No serious adverse effects, such as brain edema, hemorrhage or seizure were observed, nor systemic toxicities. Conclusion: Local immunotherapy with TNF-SAM2 may safely contribute to therapeutic efficacy in some patients with malignant glioma.
ISSN:0250-7005
1791-7530